转换酶抑制剂、血管紧张素受体阻滞剂与心房颤动

心房颤动(Af)为最常见的心律失常,常与心血管发病率和死亡率相关,Af常常需要触发机制诱发及有利的电生理或解剖底物维持,近年对触发Af底物发展这一新的治疗策略产生了兴趣,基础和临床试验资料提示调节肾素-血管紧张素-醛固酮系统(RAAS)或许可减少心脏重塑和Af,现对RAAS抑制剂治疗和预防Af的机制、基础和临床研究结果以及正在进行的临床研究等进行简要综述。

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with Atrial Fibrillation

Atrial fibrillation (Af) is the most common sustained cardiac arrhythmia and is associated with substantial cardiovascular morbidity and mortality. Af usually requires a trigger for initiation and a favourable electrophysiological and/or anatomical substrate for maintenance. There is increasing interest in novel therapeutic approaches that target Af substrate development. The initial basic science and clinical trials suggest that modulation of RAAS appears to reduce both remodelling and Af. This article summarizes mechanisms of treatment and prevention with ACEI and ARBs of Af, and the results of basic scientific research and clinial trials, and ongoing clinical trials.